Novel associations of VKORC1 variants with higher acenocoumarol requirements.

ABSTRACT:

Background

Algorithms combining both clinical and genetic data have been developed to improve oral anticoagulant therapy. Three polymorphisms in two genes, VKORC1 and CYP2C9, are the main coumarin dose determinants and no additional polymorphisms of any relevant pharmacogenetic importance have been identified.

Objectives

To identify new genetic variations in VKORC1 with relevance for oral anticoagulant therapy.

Methods and results

3949 consecutive patients taking acenocoumarol were genotyped for the VKORC1 rs9923231 and CY2C9* polymorphisms. Of these, 145 patients with a dose outside the expected range for the genetic profile determined by these polymorphisms were selected. Clinical factors explained the phenotype in 88 patients. In the remaining 57 patients, all with

SUBMITTER: Anton AI 

PROVIDER: S-EPMC3656883 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature